The DOI matches its Crossref record; 54 of the 60 references it cites were found in a registry or an index.
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
Open accessAbstract
Establishment of primary mouse embryo fibroblasts (MEFs) as continuously growing cell lines is normally accompanied by loss of the p53 or p19(ARF) tumor suppressors, which act in a common biochemical pathway. myc rapidly activates ARF and p53 gene expression in primary MEFs and triggers replicative crisis by inducing apoptosis. MEFs that survive myc overexpression sustain p53 mutation or ARF loss during the process of establishment and become immortal. MEFs lacking ARF or p53 exhibit an attenuated apoptotic response to myc ab initio and rapidly give rise to cell lines that proliferate in chemically defined medium lacking serum. Therefore, ARF regulates a p53-dependent checkpoint that safeguards cells against hyperproliferative, oncogenic signals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“p19 Arf has been shown to inhibit Mdm2-mediated degradation of p53 (19-21) and is clearly required for activation of p53 in response to aberrant cell cycle entry (19) and oncogene activation (22-24).”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“However, under stressful conditions, such as when oncogenes are activated, loss of Arf results in deregulated Mdm2 and the inability of a cell to effectively activate p53 (Eischen, et al., 1999; Schmitt, et al., 1999; Zindy, et al., 1998).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Zindy, et al., 1998
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Self-citationOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“Expression of activated ras in primary MEFs inhibits cell growth (Serrano et al. 1997), whereas overexpression of myc in these same cells triggers apoptosis, a process further aggravated by withdrawal of serum survival factors (Evan et al. 1992).”
BackgroundMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,691
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 2×
“In turn, Mdm2 acts in a feedback loop to catalyze p53 ubiquitination and degrada- tion, limiting the p53 response (Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997).”
BackgroundInduction of apoptosis in fibroblasts by c-myc protein
Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M. W., Waters, C. M., Penn, L. Z., & Hancock, D. C. (1992) · Cell · doi:10.1016/0092-8674(92)90123-t · Cited by 2,941
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Research works printed but not linked: 1
- 10.1126/science.256.5058.827 · DOI
Cited by
Sorted by citations
Items 701–800 of 1,001
Old, J. B., Kratzat, S., Höllein, A., Graf, S., Nilsson, J. A., Nilsson, L. M., Nakayama, K. I., Peschel, C., Cleveland, J. L., & Keller, U. B. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0232 · Cited by 32
Self-citationWang, W. J., Luo, J., Liang, Y., & Li, X. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4867 · Cited by 32
Inactivation of Myc-induced p53-dependent apoptosis in human tumors
Arsenian‐Henriksson, M., Selivanova, G., Lindström, M. S., & Wiman, K. G. (2001) · APOPTOSIS · doi:10.1023/a:1009644716727 · Cited by 32
Upregulation of chicken p15INK4b at senescence and in the developing brain
Kim, S., Rowe, J., Fujii, H., Jones, R., Schmierer, B., Kong, B. ‐., Kuchler, K., Foster, D. N., Ish‐Horowicz, D., & Peters, G. (2006) · Journal of Cell Science · doi:10.1242/jcs.02989 · Cited by 35
Hernández, I., Maddison, L. A., Wei, Y., DeMayo, F. J., Petras, T., Li, B., Gingrich, J. R., Rosen, J. M., & Greenberg, N. M. (2003) · PubMed · Cited by 32
Polyoma virus disrupts ARF signaling to p53
Lomax, M. E., & Fried, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204717 · Cited by 32
Carrillo, A. M., Hicks, M., Khabele, D., & Eischen, C. M. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0089 · Cited by 31
Self-citationPolycomb Group Protein Bmi1 Is Required for Growth of RAF Driven Non-Small-Cell Lung Cancer
Becker, M., Korn, C. B., Sienerth, A. R., Voswinckel, R., Luetkenhaus, K., Ceteci, F., & Rapp, U. R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004230 · Cited by 31
Adams, C. M., & Eischen, C. M. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.9 · Cited by 31
Self-citationAberrant expression of p14 ARF in human cancers: A new biomarker?
Inoue, K., & Fry, E. A. (2018) · Tumor and Microenvironment · doi:10.4103/tme.tme_24_17 · Cited by 31
Expression of theArftumor suppressor gene is controlled by Tgfβ2 during development
Freeman-Anderson, N. E., Zheng, Y., McCalla-Martin, A. C., Treanor, L. M., Zhao, Y. D., Garfin, P. M., He, T., Mary, M. N., Thornton, J. D., Anderson, C., et al. (2009) · Development · doi:10.1242/dev.033548 · Cited by 34
Physical and Functional Interaction between Ribosomal Protein L11 and the Tumor Suppressor ARF
Dai, M., Challagundla, K. B., Sun, X., Palam, L. R., Zeng, S. X., Wek, R. C., & Lu, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.311902 · Cited by 31
Steering Cell Migration Using Microarray Amplification of Natural Directional Persistence
Kumar, G., Co, C. C., & Ho, C. (2011) · Langmuir · doi:10.1021/la2000206 · Cited by 31
Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses
Timofeev, O. N., Klimovich, B., Schneikert, J., Wanzel, M., Pavlakis, E., Noll, J., Mutlu, S., Elmshäuser, S., Nist, A., Mernberger, M., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2019102096 · Cited by 31
Alfano, D., Votta, G., Schulze, A., Downward, J., Caputi, M., Stoppelli, M. P., & Iaccarino, I. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01442-09 · Cited by 31
A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis
Odvody, J., Vincent, C. T., Arrate, M. P., Grieb, B. C., Wang, S., Garriga, J., Lozano, G., Iwakuma, T., Haines, D. S., & Eischen, C. M. (2010) · Oncogene · doi:10.1038/onc.2010.82 · Cited by 31
Self-citationPTEN Deletion Leads to Up-regulation of a Secreted Growth Factor Pleiotrophin
Li, G., Hu, Y., Huo, Y., Liu, M., Freeman, D., Gao, J., Liu, X., Wu, D.-C., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512509200 · Cited by 32
Lloyd, A. C. (2000) · Nature Cell Biology · doi:10.1038/35004078 · Cited by 31
Context-specific roles for paracrine IL-6 in lymphomagenesisPreprint
Gilbert, L. A., & Hemann, M. T. (2012) · Genes & Development · doi:10.1101/gad.197590.112 · Cited by 31
Kreuzaler, P. A., Clarke, M. A., Brown, E., Wilson, C. H., Kortlever, R. M., Piterman, N., Littlewood, T. D., Evan, G. I., & Fisher, J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903485116 · Cited by 30
Porter, L., & McCaughan, F. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.007 · Cited by 30
Growth-promoting and tumourigenic activity of c-Myc is suppressed by Hhex
Marfil, V., Blazquez, M., Serrano, F., Castell, J. V., & Bort, R. (2014) · Oncogene · doi:10.1038/onc.2014.240 · Cited by 30
Reactive Oxygen Species and Oncoprotein Signaling-A Dangerous Liaison
Chong, S. J. F., Lai, J. X. H., Eu, J. Q., Bellot, G. L., & Pervaiz, S. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7441 · Cited by 30
Oncogenic RUNX3: A Link between p53 Deficiency and MYC Dysregulation.
Date, Y., & Ito, K. (2020) · PubMed · doi:10.14348/molcells.2019.0285 · Cited by 30
Transcription factor‐mediated proliferation and apoptosis in benign and malignant thyroid lesions
Letsas, Κ. P., Frangou‐Lazaridis, M., Skyrlas, A., Tsatsoulis, A. A., & Malamou‐Mitsi, V. (2005) · Pathology International · doi:10.1111/j.1440-1827.2005.01899.x · Cited by 30
Decreased Mdm2 expression inhibits tumor development induced by loss of ARF
Wang, P., Greiner, T. C., Lushnikova, T., & Eischen, C. M. (2006) · Oncogene · doi:10.1038/sj.onc.1209411 · Cited by 29
Self-citationInflammatory Disease and Lymphomagenesis Caused by Deletion of the Myc Antagonist Mnt in T Cells
Dezfouli, S., Bakke, A. C., Huang, J., Wynshaw-Boris, A. J., & Hurlin, P. J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2080-2092.2006 · Cited by 29
Functional role of RRS 1 in breast cancer cell proliferation
Song, J., Ma, Z., Hua, Y., Xu, J., Li, N., Ju, C., & Hou, L. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13922 · Cited by 29
Non-Canonical Functions of the ARF Tumor Suppressor in Development and Tumorigenesis
Lаgopati, N., Belogiannis, K., Angelopoulou, A., Papaspyropoulos, A., & Gorgoulis, V. G. (2021) · Biomolecules · doi:10.3390/biom11010086 · Cited by 30
The ARF Tumor Suppressor: Keeping Myc on a Leash
Gregory, M. A., Qi, Y., & Hann, S. R. (2004) · Cell Cycle · doi:10.4161/cc.4.2.1491 · Cited by 29
p53-independent apoptosis is induced by the p19ARF tumor suppressor
Tsuji, K., Mizumoto, K., Sudo, H., Kouyama, K., Ogata, E., & Matsuoka, M. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00723-4 · Cited by 29
Hzf regulates adipogenesis through translational control of C/EBPα
Kawagishi, H., Wakoh, T., Uno, H., Maruyama, M., Moriya, A., Morikawa, S., Okano, H., Sherr, C. J., Takagi, M., & Sugimoto, M. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.76 · Cited by 28
Self-citationReactivating the ARF-p53 axis in AML cells by targeting ULF
Chen, D., Yoon, J., & Gu, W. J. (2010) · Cell Cycle · doi:10.4161/cc.9.15.12355 · Cited by 33
A Role for E2F Activities in Determining the Fate of Myc-Induced Lymphomagenesis
Rempel, R. E., Mori, S., Gasparetto, M., Glozak, M. A., Andrechek, E. R., Adler, S., Laakso, N., Lagoo, A. S., Storms, R. W., Smith, C., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000640 · Cited by 28
Genetic Modeling of Glioma Formation in Mice
Begemann, M., Fuller, G. N., & Holland, E. C. (2002) · Brain Pathology · doi:10.1111/j.1750-3639.2002.tb00428.x · Cited by 28
DNA Damage Responses and Chemosensitivity in the E -myc Mouse Lymphoma ModelPreprint
Schmitt, C. A., Wallace-Brodeur, R. R., Rosenthal, C., McCurrach, M. E., & Lowe, S. W. (2000) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2000.65.499 · Cited by 28
McAnulty, J., & DiFeo, A. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249486 · Cited by 28
Pan, M., & Blattner, C. (2021) · Cancers · doi:10.3390/cancers13040745 · Cited by 27
Zheng, Y., Zhao, Y. D., Gibbons, M. A., Abramova, T. V., Chu, P. Y., Ash, J. D., Cunningham, J. M., & Skapek, S. X. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.128959 · Cited by 27
Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network
Inoue, K., & Fry, E. A. (2018) · Cancer Investigation · doi:10.1080/07357907.2018.1533965 · Cited by 27
Regulatory Network of ARF in Cancer Development.
Ko, A., Han, S. Y., & Song, J. (2018) · Europe PMC (PubMed Central) · doi:10.14348/molcells.2018.0100 · Cited by 27
Alternative product of the p16/CKDN2A locus connects the Rb and p53 tumor suppressors
James, M. C., & Peters, G. G. (2000) · Springer eBooks · doi:10.1007/978-1-4615-4253-7_7 · Cited by 27
Deregulation of the Cell Cycle by the Epstein–Barr Virus
O’Nions, J., & Allday, M. J. (2004) · Advances in cancer research · doi:10.1016/s0065-230x(04)92006-4 · Cited by 28
p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice
Calvo, J. A., Draheim, K., Bhasin, M., & Kelliher, M. A. (2005) · Oncogene · doi:10.1038/sj.onc.1209326 · Cited by 27
Monoclonal Antibodies to the Mouse p19 Arf Tumor Suppressor Protein
Bertwistle, D., Zindy, F., Sherr, C. J., & Roussel, M. F. (2004) · Hybridoma and Hybridomics · doi:10.1089/hyb.2004.23.293 · Cited by 27
Self-citationIdentification of Myc-mediated Death Response Pathways by Microarray Analysis
Yu, Q., He, M., Lee, N. H., & Liu, E. T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111403200 · Cited by 27
Pruschy, M. N., Wirbelauer, C., Glanzmann, C., Bodis, S. B., & Krek, W. (1999) · PubMed · Cited by 27
Müer, A., Overkamp, T., Gillissen, B. F., Richter, A., Pretzsch, T., Milojkovic, A., Dörken, B., Daniel, P. T., & Hemmati, P. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.314898 · Cited by 26
The Tumor Suppressor ARF Regulates Innate Immune Responses in Mice
Través, P. G., López-Fontal, R., Luque, A., & Hortelano, S. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1004070 · Cited by 27
Never-ageing cellular senescence
Öğrünç, M., & di Fagagna, F. D. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.003 · Cited by 26
MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer
Soto‐Feliciano, Y. M., Zhu, C., Morris, J. P., Huang, C., Koche, R. P., Ho, Y.-J., Banito, A., Chen, C.-W. D., Shroff, A., Tian, S., et al. (2023) · eLife · doi:10.7554/elife.80854 · Cited by 26
Divergent Roles of PAX2 in the Etiology and Progression of Ovarian Cancer
Al-Hujaily, E. M., Tang, Y., Yao, D., Carmona, E., Garson, K., & Vanderhyden, B. C. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0121-t · Cited by 26
Marquez, N., Chappell, S. C., Sansom, O. J., Clarke, A. R., Court, J., Errington, R. J., & Smith, P. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206876 · Cited by 26
Ulanet, D., & Hanahan, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012454 · Cited by 26
p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors
Yu, D., Carroll, M. P., & Thomas‐Tikhonenko, A. (2007) · Blood · doi:10.1182/blood-2006-10-050294 · Cited by 26
Ota, S., Zhou, Z.-Q., Link, J. M., & Hurlin, P. J. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp195 · Cited by 27
Luo, D., Hu, W., Chen, S., Xiao, Y., Sun, Y., & Zhu, Z. (2008) · Biology of Reproduction · doi:10.1095/biolreprod.108.074203 · Cited by 26
Harrington, C. T., Sotillo, E., Robert, A., Hayer, K. E., Bogusz, A. M., Psathas, J. N., Yu, D., Taylor, D. M., Dang, C. V., Klein, P. S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0454-4 · Cited by 28
Integration of the PRB and P53 Cell Cycle Control Pathways
Stewart, C. L., Soria, A. M., & Hamel, P. A. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1010615822317 · Cited by 27
Oya, N., Zölzer, F., Werner, F., & Streffer, C. (2003) · Strahlentherapie und Onkologie · doi:10.1007/s00066-003-0973-8 · Cited by 26
c-Myc does not prevent glucocorticoid-induced apoptosis of human leukemic lymphoblasts
Loeffler, M. W., Ausserlechner, M. J., Tonko, M., Hartmann, B. L., Bernhard, D., Geley, S., Helmberg, A., & Kofler, R. (1999) · Oncogene · doi:10.1038/sj.onc.1202820 · Cited by 26
The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
D’Amico, M., Wu, K., Vizio, D. D., Reutens, A. T., Stahl, M. C., Fu, M., Albanese, C., Russell, R. G., Muller, W. J., White, M. A., et al. (2003) · PubMed · Cited by 26
The ARF/Oncogene Pathway Activates p53 Acetylation within the DNA Binding Domain
Mellert, H. S., Sykes, S. M., Murphy, M. E., & McMahon, S. B. (2007) · Cell Cycle · doi:10.4161/cc.6.11.4343 · Cited by 32
David-Pfeuty, T., & Nouvian-Dooghe, Y. (2002) · Oncogene · doi:10.1038/sj.onc.1205871 · Cited by 26
Zeng, X., Keller, D., Wu, L., & Lu, H. (2000) · PubMed · Cited by 26
The DNA Damage Checkpoint and Human CancerPreprint
Schultz, L. B., Chehab, N. H., Malikzay, A., DiTullio, R. A., Stavridi, E. S., & Halazonetis, T. D. (2000) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2000.65.489 · Cited by 26
The Nucleolus and Ribosomal Genes in Aging and Senescence
Hein, N., Sanij, E., Quin, J. E., Katherine, M., Ganley, A. R. D., & Ross, D. (2012) · InTech eBooks · doi:10.5772/34581 · Cited by 25
The ARF Tumor Suppressor Regulates Bone Remodeling and Osteosarcoma Development in Mice
Rauch, D. A., Hurchla, M. A., Harding, J. C., Deng, H., Shea, L. K., Eagleton, M. C., Niewiesk, S., Lairmore, M. D., Piwnica-Worms, D. R., Rosol, T. J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015755 · Cited by 25
Meng, X., Carlson, N. R., Dong, J., & Zhang, Y. (2015) · Oncogene · doi:10.1038/onc.2015.39 · Cited by 25
Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia
Volanakis, E. J., Williams, R. T., & Sherr, C. J. (2009) · Blood · doi:10.1182/blood-2009-07-233346 · Cited by 26
Self-citationTomicic, M. T., Krämer, F., Nguyen, A., Schwarzenbach, C., & Christmann, M. (2021) · Cancers · doi:10.3390/cancers13092019 · Cited by 28
Stabilized beta-catenin immortalizes colonic epithelial cells.
Wagenaar-Miller, R. A., Crawford, H. C., & Matrisian, L. M. (2001) · PubMed · Cited by 25
Jiang, X., Tsang, Y. H., & Yu, Q. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.01.024 · Cited by 25
Hiebert, S. W., Reed-Inderbitzin, E. F., Amann, J. M., Irvin, B. J., Durst, K. L., & Linggi, B. E. (2003) · Blood Cells Molecules and Diseases · doi:10.1016/s1079-9796(03)00021-4 · Cited by 26
Mdm2 Regulates p53 Independently of p19ARF in Homeostatic Tissues
O’Leary, K. A., Mendrysa, S. M., Vaccaro, A. M., & Perry, M. E. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.24.1.186-191.2004 · Cited by 25
Post-Translational Regulation of ARF: Perspective in Cancer
Seo, J., Seong, D., Lee, S. R., Oh, D., & Song, J. (2020) · Biomolecules · doi:10.3390/biom10081143 · Cited by 25
Cencioni, C., Scagnoli, F., Spallotta, F., Nasi, S., & Illi, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044217 · Cited by 28
Baur, B. A., & Bozdag, S. (2015) · Journal of Computational Biology · doi:10.1089/cmb.2014.0296 · Cited by 24
NMI mediates transcription-independent ARF regulation in response to cellular stresses
Li, Z., Hou, J., Sun, L., Wen, T., Wang, L., Zhao, X., Xie, Q., & Zhang, S. Q. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-04-0304 · Cited by 25
Roles of N‐Myc and STAT interactor in cancer: From initiation to dissemination
Pruitt, H. C., Devine, D. J., & Samant, R. S. (2016) · International Journal of Cancer · doi:10.1002/ijc.30043 · Cited by 24
Hutchison, T., Malu, A., Yapindi, L., Bergeson, R., Peck, K., Romeo, M., Harrod, C. K., Pope, J., Smitherman, L., Gwinn, W., et al. (2018) · Virology · doi:10.1016/j.virol.2018.05.007 · Cited by 24
Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B‐cell lymphoma
Muris, J. J. F., Meijer, C. J. L. M., Ossenkoppele, G. J., Vos, W., & Oudejans, J. J. (2006) · Hematological Oncology · doi:10.1002/hon.774 · Cited by 25
RNA polymerase III transcription is repressed in response to the tumour suppressor ARF
Morton, J. P., Kantidakis, T., & White, R. J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm208 · Cited by 24
E2F activity is essential for survival of Myc-overexpressing human cancer cells
Santoni‐Rugiu, E., Duro, D., Farkas, T., Mathiasen, I. S., Jäättelä, M., Bártek, J., & Lukas, J. (2002) · Oncogene · doi:10.1038/sj.onc.1205828 · Cited by 24
Gene expression profiling of E2F-1-induced apoptosis
Jamshidi‐Parsian, A., Dong, Y., Zheng, X., Zhou, H. S., Zacharias, W., & McMasters, K. M. (2004) · Gene · doi:10.1016/j.gene.2004.09.030 · Cited by 24
Cyclin-Dependent Kinase Synthetic Lethality Partners in DNA Damage Response
Kciuk, M., Gielecińska, A., Mujwar, S., Mojzych, M., & Kontek, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073555 · Cited by 24
Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
Jy, L., Bhandare, R. R., Boddu, S. H. S., SHAIK, A. B., Saktivel, L. P., Gupta, G., Negi, P., Barakat, M. M., Singh, S. K., Dua, K., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116275 · Cited by 25
Díaz‐Rodriguez, E., García-Lavandeira, M., Pérez-Romero, S., Senra, A., Cañibano, C., Palmero, I., Borrello, M. G., Diéguez, C., & Álvarez, C. V. (2011) · Oncogene · doi:10.1038/onc.2011.458 · Cited by 24
Högstrand, K., Hejll, E., Sander, B., Rozell, B., Larsson, L., & Grandien, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031366 · Cited by 23
Tursiella, M. L., Bowman, E., Wanzeck, K. C., Throm, R. E., Liao, J., Zhu, J., & Sample, C. E. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004415 · Cited by 23
Vecchio, E., Golino, G., Pisano, A., Albano, F., Falcone, C., Ceglia, S., Iaccino, E., Mimmi, S., Fiume, G., Giurato, G., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1557-6 · Cited by 23
Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency
Zwolińska, A., Whiting, A. H., Beekman, C., Sedivy, J. M., & Marine, J. (2011) · Oncogene · doi:10.1038/onc.2011.507 · Cited by 24
Physical and Functional Interaction of the p14ARF Tumor Suppressor with Ribosomes
Rizos, H., McKenzie, H. A., Ayub, A. L. P., Woodruff, S., Becker, T. M., Scurr, L. L., Stahl, J., & Kefford, R. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m609405200 · Cited by 23
Joseph, J., Wajapeyee, N., & Somasundaram, K. (2005) · International Journal of Cancer · doi:10.1002/ijc.20842 · Cited by 23
Carneiro, C., Jiao, M. S., Hu, M., Shaffer, D. R., Park, M., Pandolfi, P. P., Cordon‐Cardo, C., & Koff, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206163 · Cited by 23
Jeffers, J. R., Pinto, E. M., Rehg, J. E., Clay, M. R., Wang, J., Neale, G. A. M., Heath, R. J., Lozano, G., Lalli, E., de Figueiredo, B. C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1750 · Cited by 22
Neault, M., Couteau, F., Bonneau, É., Guire, V. D., & Mallette, F. A. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.04.001 · Cited by 23
Molecular targeted therapies for diffuse large B‐cell lymphoma based on apoptosis profiles
Cillessen, S. A. G. M., Meijer, C. J. L. M., Notoya, M., Ossenkoppele, G. J., & Oudejans, J. J. (2009) · The Journal of Pathology · doi:10.1002/path.2670 · Cited by 22
Hemmati, P., Normand, G., Gillissen, B. F., Wendt, J., Dörken, B., & Daniel, P. T. (2008) · Oncogene · doi:10.1038/onc.2008.193 · Cited by 23
Peli1 Modulates the Subcellular Localization and Activity of Mdmx
Li, D., Tavana, O., Sun, S., & Gu, W. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3531 · Cited by 22
Metadata
- Authors
- Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 1998-08-01
- Volume
- 12
- Issue
- 15
- Pages
- 2424-2433
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC317045
- OpenAlex
- W2046958356
- Cited by
- 1,245
- References
- 60
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 14 · 2023: 32 · 2022: 10 · 2021: 27 · 2020: 15 · 2019: 22 · 2018: 15 · 2017: 23 · 2016: 28 · 2015: 19 · 2014: 43 · 2013: 45 · 2012: 46
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- St. Jude Children's Research Hospital (CA21765)
- American Lebanese Syrian Associated Charities (CA 21765)
- National Institutes of Health (5r01ca056819-08, CA21765))
- National Cancer Institute (CA-71907, CA56819, P30CA021765, P01CA071907)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 44158, R01DK044158)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- MYC signaling, ARF tumor suppressor, p53, apoptosis, cell immortalization, p19ARF, TP53 mutation, oncogenic transformation
- MeSH terms
- Animals, Cell Division, Cell Line, Humans, Models, Biological, Mutation, Proteins, Signal Transduction, Gene Expression, Genes, Tumor Suppressor, Genes, p53, Genes, myc, Apoptosis, Gene Deletion, Tumor Suppressor Protein p14ARF, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
